# Evaluation of Pharmacokinetic Interaction Between GSK3640254 and Caffeine, Metoprolol, Montelukast, Flurbiprofen, Omeprazole, Midazolam, Digoxin, and Pravastatin in Healthy Adults

> **NCT04425902** · PHASE1 · COMPLETED · sponsor: **ViiV Healthcare** · enrollment: 20 (actual)

## Conditions studied

- HIV Infections

## Interventions

- **DRUG:** GSK3640254 200 mg
- **DRUG:** Caffeine 200 mg
- **DRUG:** Metoprolol 100 mg
- **DRUG:** Montelukast 10 mg
- **DRUG:** Flurbiprofen 100 mg
- **DRUG:** Omeprazole 40 mg
- **DRUG:** Midazolam 5 mg (2.5 mL)
- **DRUG:** Digoxin 0.25 mg
- **DRUG:** Pravastatin 40 mg

## Key facts

- **NCT ID:** NCT04425902
- **Lead sponsor:** ViiV Healthcare
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-12-16
- **Primary completion:** 2021-03-10
- **Final completion:** 2021-03-10
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2024-01-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04425902

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04425902, "Evaluation of Pharmacokinetic Interaction Between GSK3640254 and Caffeine, Metoprolol, Montelukast, Flurbiprofen, Omeprazole, Midazolam, Digoxin, and Pravastatin in Healthy Adults". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04425902. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*